Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Zsofia K StadlerAnna MaioDebyani ChakravartyYelena M KemelMargaret SheehanErin Salo-MullenKaitlyn TkachukChristopher J FongBastien NguyenAmanda ErakkyKaren A CadooYing L LiuMaria Isabel CarloAlicia J LathamHongxin ZhangRitika KundraShaleigh SmithJesse GalleCarol AghajanianNadeem Abu-RustumMarjorie G ZaudererEileen M O'ReillyMichael J MorrisWassim AbidaMichael F WalshAlexander E DrilonGowtham JayakumaranAhmet ZehirMarc LadanyiOzge Ceyhan-BirsoyDavid B SolitNikolaus SchultzMichael F BergerDiana L MandelkerLuis A DiazKenneth OffitMark E RobsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype-directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.